{ "schemaVersion": "deck-intelligence.v1", "id": "019de073-a59c-77cf-8e75-229e6c5c9530", "slug": "74412512a1adb89488775a4a2b6a1b7b", "title": "Avenue Therapeutics | IPO Presentation Deck | 30 slides", "subtitle": "Avenue Therapeutics · 2022-10", "author": "Avenue Therapeutics", "date": "2022-10-01 00:00:00", "pageCount": 30, "kind": "regulatory-filing", "orientation": "landscape", "aspectRatio": 1.7761332, "document": { "id": "019de073-a59c-77cf-8e75-229e6c5c9530", "slug": "74412512a1adb89488775a4a2b6a1b7b", "title": "Avenue Therapeutics | IPO Presentation Deck | 30 slides", "rawTitle": "Avenue Therapeutics | IPO Presentation Deck | 30 slides", "authorId": "avenue-therapeutics", "authorName": "Avenue Therapeutics", "authorDisplay": "Avenue Therapeutics", "kind": { "slug": "regulatory-filing", "label": "Regulatory filing" }, "sourceType": { "slug": "investment_bank", "label": "Investment bank" }, "fileName": "2022-10__avenue-therapeutics__ipo__74412512.pdf", "sourceUrl": "https://www.slidebook.io/company/avenue-therapeutics/presentation/74412512a1adb89488775a4a2b6a1b7b/", "sourceDate": "2022-10-06 00:00:00", "presentationDate": "2022-10-01 00:00:00", "ingestedAt": "2026-04-30 22:12:48.770392+00", "status": "ready", "pageCount": 30, "orientation": "landscape", "aspectRatio": 1.7761332, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": "biotechnology", "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2022-10__avenue-therapeutics__ipo__74412512", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "IPO Presentation Deck", "deck_type_slug": null, "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 30, "pagesIndexed": 30, "pagesWithImages": 30, "pagesWithMetadata": 30, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 128, "chartCount": 7, "metricSlides": 0, "toolMatches": 3, "documentToolMatches": 0, "frameworkMatches": 10, "arcMatches": 1, "beatMatches": 5, "loopMatches": 1, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "evidence": "The document follows a similar structure to the Sequoia Pitch, with sections on problem, solution, market size, product, and team.", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 22:26:50.348188+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 11, "name": "Problem", "beatId": "5260138e-00d3-4228-841b-29589c8a9035", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 11 and 12 present the problem statement, highlighting the unmet needs in epilepsy and acute anxiety treatment.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 8, "name": "Solution", "beatId": "618a2f9e-df9a-49da-a0ea-04fb4bfa7948", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 13, "name": "Market Size", "beatId": "3c1a1939-0c77-485a-99c7-2e27cc46a9e7", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slides 13 and 14 present the market opportunity for BAER-101.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 16, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 15, "name": "Product", "beatId": "a2360b6a-b9a0-4abf-8173-d869bbb23b99", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "Slides 15 and 16 present preclinical data supporting the efficacy of BAER-101.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 29, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 28, "name": "Team", "beatId": "082cf897-b0c1-43e2-90f2-e35450751b09", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 28 and 29 present the management team and board of directors.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1", "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:26:50.556641+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "ff08f7e2-920e-40eb-8f96-2b23cfcd4f60", "evidence": "The slide is a cover slide with a logo, title, and subtitle, which is a standard element of a presentation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:11:37.098457+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null }, { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "55be8c2a-1d2e-4390-97e4-1dabf37b8e18", "evidence": "The slide presents a diagram of a process, but it is not clearly related to a specific tool.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:11:37.362458+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cec80edb-013b-42c4-bead-b8b21744e0bf", "evidence": "This slide serves as an executive summary, providing a high-level overview of BAER-101's mechanism and its potential clinical consequences.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:11:38.003958+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "b2627ef1-15a2-4f22-ad44-c5f8ee28e32f", "evidence": "The slide compares two assets across identical criteria to establish portfolio value.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "comparison_frame" }, { "matchId": "b625b7a5-46d4-4831-8d9e-16d525b89b60", "evidence": "Visual representation of project phases over time", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" }, { "matchId": "0a867ce7-8bd9-4198-8a80-f09c745dd87a", "evidence": "Sequential numbered steps indicating strategic progression", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:05.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "roadmap" }, { "matchId": "7fdb0838-3297-4cb0-85ab-9714d781fcf4", "evidence": "Comparison of BAER-101 vs Benzodiazepines", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "comparison_frame" }, { "matchId": "6e42fbf2-7c80-448f-bf1f-14b8c76603fe", "evidence": "Visual representation of market segments within a larger total addressable market.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "market-segmentation-pyramid" }, { "matchId": "2acfbd43-92c7-41fa-bce8-31e8e08a1a42", "evidence": "The slide uses a table to compare BAER-101 against competitors based on selectivity and clinical phase.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" }, { "matchId": "160e1178-f6de-41bb-9a63-152c764124c2", "evidence": "Three-step sequential roadmap", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:27:07.743+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "process" }, { "matchId": "6539a2af-4d20-4d20-a5c9-315d52675615", "evidence": "Central circle with two side boxes connected by arrows", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "hub-spoke" }, { "matchId": "d529b528-b335-4eb5-ad25-224ed84c38ad", "evidence": "Chronological presentation of regulatory events", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "timeline" }, { "matchId": "2eec1bae-0a6e-4486-9195-f24f9535bf0a", "evidence": "Sequential numbered steps representing strategic focus areas.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.837+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "roadmap" } ], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/-TA6c74k5aEmIL5qW5eHlFYytFPLaiJF3IcXDRi0Fi4/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83NDQxMjUxMmExYWRiODk0ODg3NzVhNGEyYjZhMWI3Yi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 31, "componentCount": 4, "textChars": 234, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:05.85+00", "seconds": 2.588, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/1", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-1", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.2, "x": 0.78, "y": 0.03 }, "kind": "disclaimer", "text": "Issuer Free Writing Prospectus Filed Pursuant to Rule 433 Registration Statement No. 333-267206 (Preliminary Prospectus dated October 6, 2022)", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.85+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "470abe70-5243-40de-8ba5-823d514e9959", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.25, "x": 0.03, "y": 0.88 }, "kind": "image", "text": "Avenue Therapeutics", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.85+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "09ecb342-6ef0-4683-a422-86780ad34253", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.33, "y": 0.91 }, "kind": "paragraph", "text": "AVENUE THERAPEUTICS, INC. | NASDAQ: ATXI | OCTOBER 2022", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.85+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "505ca771-da9b-4a92-a3be-73d768e19141", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.35, "x": 0.03, "y": 0.6 }, "kind": "title", "text": "Corporate Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.85+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "706c3e68-a6da-40b9-b2e0-e8280db6566f", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Slide recipe: Cover", "slug": "cover-slide", "status": "active", "bestFor": null, "canonId": "019df269-2a08-767d-9128-e7431e6fe8a3", "version": 1, "bodyDocId": "019df269-29e5-7738-b5fa-6892e5dc8e65", "description": "The first ten seconds. Build it deliberately.", "familyLabel": "slide-recipe", "categoryName": "Slide", "categorySlug": "slide" }, "agent": "designer", "layer": "slide", "agents": [ "designer" ], "matchId": "ff08f7e2-920e-40eb-8f96-2b23cfcd4f60", "evidence": "The slide is a cover slide with a logo, title, and subtitle, which is a standard element of a presentation.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:11:37.098457+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 1, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "thumbSrc": "https://imgproxy.kitesheet.com/OPu-8rgwOp1fE1bFgRcqX6BNwqZs0deXQDDt0d9GSfg/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83NDQxMjUxMmExYWRiODk0ODg3NzVhNGEyYjZhMWI3Yi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/KLDZQXLDXyFGVCLCvj305hNj8kI5XL_17le3MPvtezU/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83NDQxMjUxMmExYWRiODk0ODg3NzVhNGEyYjZhMWI3Yi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/j4GbOXHSk8jb2z1oBr829bUfhRSoSfKDWm_3J2OD5hs/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy83NDQxMjUxMmExYWRiODk0ODg3NzVhNGEyYjZhMWI3Yi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "front_matter", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 12, "componentCount": 2, "textChars": 160, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:05.384+00", "seconds": 2.081, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/2", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-2", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.75, "w": 0.92, "x": 0.04, "y": 0.18 }, "kind": "disclaimer", "text": "Free Writing Prospectus: This free writing prospectus relates to the proposed public offering of securities of Avenue Therapeutics, Inc. ...", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.384+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e311db9-ab1b-41b0-95c8-9dde75c7a325", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.25, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "Notice & Disclaimers", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.384+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cd7c6604-697d-4ee8-ad18-aa73a3775b63", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 3, "type": "setup", "function": "establish_context", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 27, "componentCount": 2, "textChars": 337, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:05.377+00", "seconds": 2.05, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/3", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-3", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.928, "x": 0.036, "y": 0.26 }, "kind": "table", "text": "Issuer: Avenue Therapeutics, Inc.; Ticker / Exchange: NASDAQ / ATXI; Securities Offered: Common Stock and 100% Warrant Coverage; Offering Size: $12 million; Over-Allotment Option: 15% of Offering; Use of Proceeds: $3 million for share repurchase, remainder for general corporate purposes; Underwriter: Aegis Capital Corp.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.377+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d5292058-42b6-4543-9e9b-6f00c4493087", "parentComponentId": null }, { "bbox": { "h": 0.045, "w": 0.28, "x": 0.036, "y": 0.115 }, "kind": "title", "text": "Offering Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.377+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6bfc9d83-9c40-4695-afdc-f9b7a41a07dc", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 4, "type": "setup", "title": "The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 402, "nDataPoints": 0, "notes": "The slide features a high-quality illustration of neurons, emphasizing the CNS focus of the company.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:06.284+00", "seconds": 2.712, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/4", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-4", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 1, "w": 0.38, "x": 0.62, "y": 0 }, "kind": "image", "text": "Illustration of neurons", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.284+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f57d8c66-ab7a-4de1-b936-9a885b071359", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.55, "x": 0.04, "y": 0.18 }, "kind": "list", "text": "Avenue Therapeutics is a specialty pharmaceutical company that seeks to develop and commercialize therapies to treat central nervous system (CNS) conditions. Our portfolio will soon include two clinical stage programs: IV Tramadol (Phase 3) and BAER-101 (Phase 1b).", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.284+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "97c2ecbb-a192-4f33-8d8d-91ceb6ffd571", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.4, "x": 0.18, "y": 0.93 }, "kind": "source-note", "text": "* Pending close of Share Contribution Agreement with Fortress Biotech, Inc. for Baergic Bio, Inc.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.284+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bc4fb3fb-3959-45ac-8606-c2fb7cb6172d", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "Executive Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.284+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "620223c7-c322-4543-8f1d-d3900099d30a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "setup", "title": "The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 4, "textChars": 449, "nDataPoints": 2, "notes": "The slide uses a simple additive equation visual to represent the growth of the company's CNS portfolio.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:06.755+00", "seconds": 3.061, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/5", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-5", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.15, "x": 0.8, "y": 0.4 }, "kind": "other", "text": "Growing CNS portfolio", "attrs": null, "canon": { "kind": { "name": "Other", "slug": "other", "status": "active", "canonId": "019de52c-fa90-743c-8bf6-20d1fbe82b6d", "version": 1, "description": "Fallback when no canonical kind applies." }, "tool": null, "subkind": { "name": "Unclassified", "slug": "unclassified", "status": "active", "canonId": "019de52d-05ca-77db-81fb-db7d4234bbc0", "version": 1, "description": null }, "framework": null }, "subkind": "unclassified", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dc61934b-cafd-480e-8234-1c00c0a02b71", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.95 }, "kind": "source-note", "text": "Note: * Contingent upon closing of the Baergic Bio acquisition; ** Market cap as of 9/8/22", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "50f00255-2f97-4555-9db0-dec52e840c3a", "parentComponentId": null }, { "bbox": { "h": 0.7, "w": 0.75, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Pipeline Asset: BAER-101, IV Tramadol; Indication: Epilepsy and acute anxiety, Post operative pain; Mechanism: Selective GABA-A 2, 3 receptor positive allosteric modulator, Opioid agonist & inhibitor of norepinephrine & serotonin re-uptake", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "98164d15-3aec-4602-9fe0-7f06498d77a2", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Our clinical stage assets address large unmet patient and market needs in the CNS therapeutic space", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ac99c37-6791-4d8f-9bae-793b2dd53dd5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b2627ef1-15a2-4f22-ad44-c5f8ee28e32f", "evidence": "The slide compares two assets across identical criteria to establish portfolio value.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:06.755+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 6, "type": "resolution", "title": "The slide uses a Gantt-style visualization to track drug development progress.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 19, "componentCount": 3, "textChars": 167, "nDataPoints": 0, "notes": "The slide uses a Gantt-style visualization to track drug development progress.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.268+00", "seconds": 4.569, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/6", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-6", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.4, "x": 0.5, "y": 0.9 }, "kind": "legend", "text": "Completed study vs Planned study", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "095333e7-1d79-4140-a4ce-b7fbad5dc328", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.9, "x": 0.05, "y": 0.2 }, "kind": "table", "text": "Pipeline matrix showing drug candidates, indications, development phases, and rights.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "66f30a88-b6d3-45b5-b9b5-eb00c94f3311", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Our pipeline has near term value inflection points", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c295d3a0-0189-44c5-b25f-53a7d3dc712a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "b625b7a5-46d4-4831-8d9e-16d525b89b60", "evidence": "Visual representation of project phases over time", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 6, "frameworkName": "gantt-chart" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 7, "type": "resolution", "title": "The slide uses a numbered process flow to indicate strategic priorities.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 1, "textChars": 65, "nDataPoints": 0, "notes": "The slide uses a numbered process flow to indicate strategic priorities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:05.434+00", "seconds": 1.718, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/7", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-7", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.88, "x": 0.06, "y": 0.32 }, "kind": "diagram", "text": "1. BAER-101, 2. IV Tramadol, 3. Acquire CNS / Rare Disease Assets", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:05.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e7905e13-7d9d-46ca-8d5f-d5a5b13e84ce", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Process flow", "slug": "process-flow", "status": "active", "bestFor": null, "canonId": "019dd9e1-4dca-76bc-8135-401836a1c4c0", "version": 1, "bodyDocId": null, "description": "Workflow, steps, sequential diagram.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "55be8c2a-1d2e-4390-97e4-1dabf37b8e18", "evidence": "The slide presents a diagram of a process, but it is not clearly related to a specific tool.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.5, "extraction": { "at": "2026-07-17 00:11:37.362458+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [ { "matchId": "0a867ce7-8bd9-4198-8a80-f09c745dd87a", "evidence": "Sequential numbered steps indicating strategic progression", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:05.434+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 7, "frameworkName": "roadmap" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 8, "type": "setup", "function": "establish_context", "rawType": "thesis_headline", "block": null, "metadata": { "slideType": "thesis_headline", "slideTypeCanon": { "name": "Thesis headline", "slug": "thesis_headline", "status": "active", "canonId": "019de52d-073a-70cb-b9f6-772a597bb5af", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "sparse", "densityScore": 10, "componentCount": 2, "textChars": 119, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.276+00", "seconds": 5.472, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/8", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-8", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.45, "w": 0.56, "x": 0.22, "y": 0.295 }, "kind": "diagram", "text": "BAER-101 branching into Epilepsy and Acute Anxiety Conditions", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.276+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7e97b68d-14db-45cf-b05c-625482e96674", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.115 }, "kind": "title", "text": "BAER-101 is being developed for epilepsy and acute anxiety", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.276+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72f77b5d-128b-4985-84e5-4601153d9df8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "618a2f9e-df9a-49da-a0ea-04fb4bfa7948", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 9, "type": "setup", "title": "Includes a scientific diagram of the GABAa receptor complex.", "function": "establish_context", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 55, "componentCount": 5, "textChars": 581, "nDataPoints": 0, "notes": "Includes a scientific diagram of the GABAa receptor complex.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:06.89+00", "seconds": 2.598, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/9", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-9", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.82 }, "kind": "callout", "text": "BAER-101 targets GABA a2 and a3 subtypes more than a1 and a5, which should have important clinical consequences", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.89+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "da9604a8-5634-48ea-bc10-4e0344ab5bdc", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.35, "x": 0.05, "y": 0.2 }, "kind": "image", "text": "Diagram of GABAa receptor structure", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Infographic", "slug": "infographic", "status": "active", "canonId": "019de52c-fe26-750c-9d7d-9f34e21324e8", "version": 1, "description": null }, "framework": null }, "subkind": "infographic", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.89+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d0072086-8001-4754-97b7-aad20771bb6f", "parentComponentId": null }, { "bbox": { "h": 0.4, "w": 0.55, "x": 0.42, "y": 0.3 }, "kind": "list", "text": "GABA receptors are the major inhibitory neurotransmitter receptors in the mammalian brain; GABA receptors have three major subunits a b y, which are organized into a pentameric structure; Each subunit has multiple subtypes (e.g., a1, a2, a3, a5) and these have different dominant functions", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.89+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "924b23c4-425a-41c4-bb4a-0f4d8e0fd57b", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.2, "x": 0.16, "y": 0.95 }, "kind": "source-note", "text": "Jacob et al., Nature Reviews Neuroscience, 2008", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.89+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ecd3eebc-9c2d-41dd-a694-388abff2e720", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.85, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "BAER-101 is a selective GABAa receptor agonist that produces anticonvulsant and anxiolytic activity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:06.89+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f6dd866-8ea6-477c-b8e9-c08995ae39c4", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Executive summary", "slug": "executive-summary", "status": "active", "bestFor": null, "canonId": "019dd9e1-4b63-72d5-9734-da757d91ca61", "version": 1, "bodyDocId": null, "description": "A condensed view of the entire argument on a single slide / block.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "cec80edb-013b-42c4-bead-b8b21744e0bf", "evidence": "This slide serves as an executive summary, providing a high-level overview of BAER-101's mechanism and its potential clinical consequences.", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 00:11:38.003958+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 9, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "618a2f9e-df9a-49da-a0ea-04fb4bfa7948", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 10, "type": "setup", "title": "The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).", "function": "compare_peers", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 75, "componentCount": 6, "textChars": 723, "nDataPoints": 20, "notes": "The table uses checkmarks to indicate the strength of effect for different GABA-A subtypes (alpha 1, 2, 3, 5).", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:07.904+00", "seconds": 3.579, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/10", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-10", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.05, "x": 0.47, "y": 0.78 }, "kind": "callout", "text": "VS", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "74c69d28-85b2-43a9-a6f1-b6be8665483d", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.43, "x": 0.53, "y": 0.72 }, "kind": "list", "text": "BAER-101 is a selective agonist at the α2 and α3 subunits. The goal of BAER-101 is to provide anticonvulsant and anxiolytic activity by minimizing adverse events and risk of tolerance and abuse", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "81e9b296-a882-4622-8a3a-c64c5a4b80f4", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.45, "x": 0.04, "y": 0.72 }, "kind": "list", "text": "Benzodiazepines (BZDs) are non-selective agonists of the alpha subunits α1, α2, α3 and α5. BZDs have an extensive adverse event profile that can limit the dose and its effectiveness: somnolence, sedation, cognitive impairment, overuse, misuse and addiction", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c93f68b7-ad3c-4b50-b8f9-b67ccf9a9c4c", "parentComponentId": null }, { "bbox": { "h": 0.48, "w": 0.92, "x": 0.04, "y": 0.21 }, "kind": "table", "text": "Table comparing therapeutic and negative effects across alpha 1, 2, 3, and 5 GABA-A subtypes.", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "008dcd40-bf31-4c5c-ae24-98bc41c12794", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "BAER-101 may have a more tolerable side effect profile compared to nonselective benzodiazepines due to greater GABA subtype selectively", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5dc47687-2fc1-4909-a0b8-cd608569dc2a", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.35, "x": 0.04, "y": 0.16 }, "kind": "title", "text": "Predicted effect of targeting GABAA subtypes", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "93d63ca8-1638-428b-a891-c62d7cff8118", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "7fdb0838-3297-4cb0-85ab-9714d781fcf4", "evidence": "Comparison of BAER-101 vs Benzodiazepines", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:07.904+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 10, "frameworkName": "comparison_frame" } ], "arcBeats": [ { "to": 10, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 8, "name": "Solution", "beatId": "618a2f9e-df9a-49da-a0ea-04fb4bfa7948", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Solution", "slug": "sequoia-pitch-solution", "status": "active", "canonId": "019dd9b8-1fb1-71d9-a260-07738d7f9c2f", "version": 1, "description": null }, "evidence": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential.", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Turn", "slug": "turn", "status": "active", "canonId": "019dd9b8-0396-702b-ac2f-9901f8dd8b54", "version": 1, "description": "The pivot — solution proposed, catalyst introduced, decision made. Common (15/20 arcs) but not universal: Triple-take, AIDA, PAS, Voyage-return and Pixar substitute it with a strong reflection or development beat." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 67, "componentCount": 5, "textChars": 902, "nDataPoints": 3, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.027+00", "seconds": 2.83, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/11", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-11", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.92, "x": 0.04, "y": 0.22 }, "kind": "list", "text": "Disease: Epilepsy is a chronic disease that manifests as recurrent seizures from abnormal electrical discharge in the brain; Affects approximately 65M patients worldwide", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e17258ba-389e-4aaf-bac6-25674b5199cd", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.92, "x": 0.04, "y": 0.69 }, "kind": "list", "text": "Unmet Need: ~50% of epilepsy patients fail 1st line treatments and ~30% of patients are not well managed with any antiseizure medications; BZDs are effective for seizures, but not well tolerated due to significant side effects", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f4973c30-4e00-49d5-9883-1cfec6baeb53", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.92, "x": 0.04, "y": 0.44 }, "kind": "list", "text": "Treatment: Standard of care is the use of one or more anti-epileptic drugs (AED); Benzodiazepines (BZDs) are a class of AED that are used to treat seizures, but are generally not used as daily medication due to side effects", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fa637344-03e0-40f1-aedc-934a5734bb35", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.16, "y": 0.95 }, "kind": "source-note", "text": "Source: CDC.gov; Kalilani L et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27761d21-8684-47fa-9e8c-775d37c8cfa6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Epilepsy patients are prescribed benzodiazepines to control seizures, but have significant unmet needs for therapies with improved safety profiles", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.027+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ef757212-f3cc-43e9-8375-76b082ac07f5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Problem", "beatId": "5260138e-00d3-4228-841b-29589c8a9035", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 11 and 12 present the problem statement, highlighting the unmet needs in epilepsy and acute anxiety treatment.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1", "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:26:50.556641+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 12, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 65, "componentCount": 5, "textChars": 815, "nDataPoints": 1, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:11.344+00", "seconds": 6.05, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/12", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-12", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.78, "x": 0.18, "y": 0.735 }, "kind": "list", "text": "BZDs are effective for panic disorder but not well tolerated due to sedation, cognitive impairment, ataxia and can develop tolerance and addiction over time", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:11.344+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0447863f-86a0-4a1a-8efe-a9caca242b47", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.78, "x": 0.18, "y": 0.505 }, "kind": "list", "text": "Panic disorder is treated with a combination of cognitive behavioral therapy and benzodiazepines (BZDs), tricyclics, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:11.344+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "a656c6b9-510d-43c9-9dc6-347cc3c150f1", "parentComponentId": null }, { "bbox": { "h": 0.22, "w": 0.78, "x": 0.18, "y": 0.215 }, "kind": "list", "text": "Panic disorder is a common form of an acute anxiety disorder manifesting as frequent panic attacks unrelated to specific situations. Manifests as intense episodes of apprehension, terror, feelings of impending doom and intense urge to flee. Affects approximately 6.8M patients in the U.S.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:11.344+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe4001c5-9a3e-4c4b-a85e-cde2df86b7ef", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.08, "x": 0.16, "y": 0.95 }, "kind": "source-note", "text": "Source: ADAA.org", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:11.344+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3f699286-0fe3-4cab-9203-322401d7e4e6", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Acute anxiety patients also utilize benzodiazepines today and have significant unmet need for therapies with improved safety profiles", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:11.344+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9988266b-9bb7-4383-9bd2-ee86a0fa3fc8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 12, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 11, "name": "Problem", "beatId": "5260138e-00d3-4228-841b-29589c8a9035", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Problem", "slug": "sequoia-pitch-problem", "status": "active", "canonId": "019dd9b8-1ed4-767b-8e05-40e733bd2311", "version": 1, "description": null }, "evidence": "Slides 11 and 12 present the problem statement, highlighting the unmet needs in epilepsy and acute anxiety treatment.", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1", "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:26:50.556641+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 13, "type": "resolution", "title": "Uses a Venn-like containment diagram to show sub-segments of a larger market.", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 608, "nDataPoints": 3, "notes": "Uses a Venn-like containment diagram to show sub-segments of a larger market.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.853+00", "seconds": 4.501, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/13", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-13", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.6, "w": 0.8, "x": 0.1, "y": 0.25 }, "kind": "diagram", "text": "Venn-style containment diagram showing Drug Resistant Epilepsy, Orphan Epilepsy, and Acute Anxiety within the Patients prescribed benzodiazepines market.", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d380d22-d21a-47cb-8dea-b77d4db8ed80", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.52, "x": 0.24, "y": 0.87 }, "kind": "legend", "text": "Patients prescribed benzodiazepines; Initial addressable population", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cb8ab760-457e-42a5-b5c6-8dc0b83beb1f", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.68, "x": 0.16, "y": 0.93 }, "kind": "source-note", "text": "Source: CDC.gov; Grand View Research, Polaris Market Research; Kalilani L et al. The epidemiology of drug-resistant epilepsy: A systematic review and meta-analysis. Epilepsia. 2018 Dec; NORD; LGS Foundation; NIH.gov; ADAA.org", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8598426c-0d79-447d-842f-db458b2801f4", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "BAER-101 can target the large market of patients prescribed BZDs by targeting drug resistant epilepsy, orphan epilepsy, or acute anxiety", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88a4584c-7f23-4ffb-bfe3-2477ecdacf9d", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.35, "x": 0.04, "y": 0.19 }, "kind": "title", "text": "BAER-101 addressable market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d8ce5d3d-a99a-4816-b266-06d1107fc78a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6e42fbf2-7c80-448f-bf1f-14b8c76603fe", "evidence": "Visual representation of market segments within a larger total addressable market.", "framework": null, "confidence": 0.7, "extraction": { "at": "2026-05-02 12:27:09.853+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 13, "frameworkName": "market-segmentation-pyramid" } ], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Market Size", "beatId": "3c1a1939-0c77-485a-99c7-2e27cc46a9e7", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slides 13 and 14 present the market opportunity for BAER-101.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1", "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:26:50.556641+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 14, "type": "setup", "title": "The slide uses a hexagonal layout to present five key product attributes.", "function": "establish_context", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "balanced", "densityScore": 36, "componentCount": 3, "textChars": 408, "nDataPoints": 1, "notes": "The slide uses a hexagonal layout to present five key product attributes.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.287+00", "seconds": 2.846, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/14", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-14", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.92, "x": 0.04, "y": 0.78 }, "kind": "callout", "text": "BAER-101 was licensed from AstraZeneca (where it was called AZD7325) in December 2019 with an extensive preclinical and clinical package", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.287+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cf2247cd-25ce-4939-a257-3be70a6ea694", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.86, "x": 0.07, "y": 0.25 }, "kind": "diagram", "text": "Selective in vitro profile, Preclinical disease model efficacy, Preclinical disease model safety and reduced abuse liability, High receptor occupancy, Safety in humans demonstrated in clinical trials in >700 patients", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.287+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "e31d7016-636a-4759-aa02-332e3e046edd", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.12 }, "kind": "title", "text": "BAER-101 has a compelling profile to address this market", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.287+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "51a2d775-b70f-478a-91d4-49d094c5529a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 14, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 13, "name": "Market Size", "beatId": "3c1a1939-0c77-485a-99c7-2e27cc46a9e7", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Market Size", "slug": "sequoia-pitch-market-size", "status": "active", "canonId": "019dd9b8-20e6-729c-bc28-05442906d032", "version": 1, "description": null }, "evidence": "Slides 13 and 14 present the market opportunity for BAER-101.", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 14, "from": 11, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "e6485657-8caf-4343-bf92-1e9c148fd1b1", "evidence": "The loop is opened on slide 11, highlighting the limitations of current treatments, and closed on slide 14, presenting BAER-101 as a solution.", "position": 0, "objective": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?", "confidence": 0.7, "extraction": { "at": "2026-07-16 22:26:50.556641+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 15, "type": "resolution", "title": "The slide notes that BAER-101 was previously known as AZD7325.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 369, "nDataPoints": 2, "notes": "The slide notes that BAER-101 was previously known as AZD7325.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.278+00", "seconds": 2.738, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/15", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-15", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.9, "x": 0.05, "y": 0.82 }, "kind": "callout", "text": "In a mouse model of Dravet syndrome BAER-101 was protective against seizures without notable sedation", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c89ddc9-aae4-439c-9c29-267ea25591c4", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.25, "x": 0.42, "y": 0.3 }, "kind": "chart", "text": "Temperature vs Dose dot plot", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Dot plot", "slug": "dot", "status": "active", "canonId": "019de52d-0235-738b-bd2b-78f8e24d7cb0", "version": 1, "description": null }, "framework": null }, "subkind": "dot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4916eda5-42ab-4d0d-b3ff-23e3c0bcdc0b", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.25, "x": 0.7, "y": 0.3 }, "kind": "chart", "text": "Percent with GTCS vs Temperature line chart", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5caff68d-06d8-4ab4-9adb-8dbf13402586", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.5, "x": 0.15, "y": 0.95 }, "kind": "disclaimer", "text": "Note: BAER-101 was previously known as AZD7325 when tested in these preclinical models", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cfb79efd-411f-45e8-b11c-9002569a8dcd", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.35, "x": 0.05, "y": 0.25 }, "kind": "image", "text": "Journal of Physiology paper snippet", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Screenshot", "slug": "screenshot", "status": "active", "canonId": "019de52c-fd87-7509-8391-3d79fb339379", "version": 1, "description": null }, "framework": null }, "subkind": "screenshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "156ef267-400c-4c54-be1e-3212e61a4cbc", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.8, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "Preclinical in vivo studies demonstrate efficacy in multiple epilepsy models", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.278+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f5d0c644-789f-4957-8f7a-74d9198f2511", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 16, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Product", "beatId": "a2360b6a-b9a0-4abf-8173-d869bbb23b99", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "Slides 15 and 16 present preclinical data supporting the efficacy of BAER-101.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 16, "type": "analysis", "title": "The slide highlights the therapeutic window of BAER-101 by showing efficacy in the punished model without significant impairment in the un-punished model.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 6, "textChars": 403, "nDataPoints": 12, "notes": "The slide highlights the therapeutic window of BAER-101 by showing efficacy in the punished model without significant impairment in the un-punished model.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.705+00", "seconds": 3.153, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/16", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-16", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.78 }, "kind": "callout", "text": "In the rat punished responding model, BAER-101 demonstrated an anxiolytic effect similar to benzodiazepines but with reduced side effects", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1f4a8683-fdf5-4324-beb7-3e1b8768d05a", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.4, "x": 0.05, "y": 0.25 }, "kind": "chart", "text": "Punished model results", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6c71aabe-199d-464b-8409-5e609d8dbd62", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.4, "x": 0.55, "y": 0.25 }, "kind": "chart", "text": "Un-punished model results", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Vertical bar chart", "slug": "bar-vertical", "status": "active", "canonId": "019de52c-fe9d-70f2-b3b7-a9ae294f5917", "version": 1, "description": null }, "framework": null }, "subkind": "bar-vertical", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "79053f74-6529-4984-aeb1-ad567e3c1f08", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.4, "x": 0.16, "y": 0.95 }, "kind": "source-note", "text": "Note: BAER-101 was previously known as AZD7325 when tested in these preclinical models", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0cbc2420-d629-4125-9451-dc09aabef501", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.85, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Preclinical in vivo studies demonstrate efficacy in multiple anxiety models", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "682d97fd-420e-4323-a111-ba6ec0a50215", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.6, "x": 0.04, "y": 0.16 }, "kind": "title", "text": "EXAMPLE: BAER-101 results in rat punished responding model", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "019de52c-fb09-739d-900c-815b0d9ac526", "version": 1, "description": null }, "framework": null }, "subkind": "subtitle", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.705+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f9e8ce1f-80c6-402f-a03c-1b3e992aec53", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 16, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 15, "name": "Product", "beatId": "a2360b6a-b9a0-4abf-8173-d869bbb23b99", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Product", "slug": "sequoia-pitch-product", "status": "active", "canonId": "019dd9b8-2259-77df-a937-8b665c8066fe", "version": 1, "description": null }, "evidence": "Slides 15 and 16 present preclinical data supporting the efficacy of BAER-101.", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 17, "type": "resolution", "title": "Includes a comparison to Cerevel's darigabat and lorazepam.", "function": "summarize", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 79, "componentCount": 7, "textChars": 915, "nDataPoints": 1, "notes": "Includes a comparison to Cerevel's darigabat and lorazepam.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.99+00", "seconds": 3.398, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/17", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-17", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.05, "w": 0.92, "x": 0.04, "y": 0.21 }, "kind": "list", "text": "BAER-101/AZD7325 was tested in over 700 subjects (healthy volunteers and patients)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0014a117-c175-4275-80c2-d4b1fc33552a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.39 }, "kind": "list", "text": "In two Phase 2 studies, BAER-101 was tested in patients with generalized anxiety disorder (GAD), but missed the primary endpoint", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0d758810-57ca-4f44-9ff7-96ccf01d6b66", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.75 }, "kind": "list", "text": "BAER-101 was also tested in a human abuse liability study where risk abuse with BAER-101 appeared lower than lorazepam (a BZD)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "aa6e3b6f-6b2c-455d-b0e2-dc4a93e5e282", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.89, "x": 0.07, "y": 0.48 }, "kind": "list", "text": "A sub analysis of the data with removal of dropouts and non-compliant patients (as measured by drug plasma levels), showed: a dose-related anxiolytic signal; a correlation between average exposure and efficacy", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bed5ed3b-3ef1-4005-99b1-99ae7015739c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.89, "x": 0.07, "y": 0.64 }, "kind": "list", "text": "Further, Cerevel's darigabat (a similar molecule) also missed the primary endpoint in the truncated GAD study and showed promising results in two Phase 1b studies in epilepsy and acute anxiety", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c41580bd-2c94-42ad-8a6e-e095ce43dc1b", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.28 }, "kind": "list", "text": "Side effects were mild or moderate with the most common side effects being dizziness and somnolence", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d815d85a-c7c2-4cf5-ab38-cefcfe7fcdaa", "parentComponentId": null }, { "bbox": { "h": 0.12, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "AstraZeneca completed 10 clinical studies and demonstrated safety across trials", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.99+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "28c1e9c6-e569-43dc-a7de-57d127899148", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 18, "type": "analysis", "title": "The chart shows BAER-101 regimens consistently resulting in lower sleepiness rates than Lorazepam.", "function": "analyze_data", "rawType": "appendix_data", "block": null, "metadata": { "slideType": "appendix_data", "slideTypeCanon": { "name": "Appendix data", "slug": "appendix_data", "status": "active", "canonId": "019de52d-078a-745b-9ee4-c15f2f539acd", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 58, "componentCount": 5, "textChars": 412, "nDataPoints": 32, "notes": "The chart shows BAER-101 regimens consistently resulting in lower sleepiness rates than Lorazepam.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.579+00", "seconds": 2.983, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/18", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-18", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.78 }, "kind": "callout", "text": "Compared to the benzodiazepine lorazepam, two dosing regimens of BAER-101 led to less sedation as captured by the measurement of sleepiness", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.579+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ac8b2f5-8a72-4a3f-ae86-df13db012fc2", "parentComponentId": null }, { "bbox": { "h": 0.5, "w": 0.5, "x": 0.25, "y": 0.25 }, "kind": "chart", "text": "Subjects experiencing sleepiness % of subjects (N=36-66)", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Line chart", "slug": "line", "status": "active", "canonId": "019de52c-ff62-778f-8f6c-a952ceae8677", "version": 1, "description": null }, "framework": null }, "subkind": "line", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.579+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7a909fd5-22df-46fa-ad6b-011fe4af5ccd", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.4, "x": 0.16, "y": 0.95 }, "kind": "source-note", "text": "Note: BAER-101 was previously known as AZD7325 when tested in these preclinical models", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.579+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5d4ea40b-a3f1-43a7-89a4-9d08eeb64915", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.45, "x": 0.04, "y": 0.19 }, "kind": "subtitle", "text": "Example: subset analysis from Phase 2 generalized anxiety study", "attrs": null, "canon": { "kind": { "name": "Subtitle", "slug": "subtitle", "status": "active", "canonId": "82d821ee-2793-42e7-8f16-c6131385a3ce", "version": 1, "description": "Header-zone supporting text near the title (= ex body.description with bbox)." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.579+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "52c283ac-bc6c-4a77-8cfe-6f9f42f19845", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.65, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "Clinical studies demonstrate positive sedation and cognition effects", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.579+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3c3525d7-8d49-4e03-bc6e-85965b37a664", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 19, "type": "setup", "title": "Includes a medical warning regarding photosensitivity.", "function": "present_solution", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "present_solution", "functionCanon": { "name": "Present solution", "slug": "present_solution", "status": "active", "canonId": "019de52d-15b8-71da-bd23-2b767850cbce", "version": 1, "description": null }, "density": "dense", "densityScore": 62, "componentCount": 5, "textChars": 1067, "nDataPoints": 0, "notes": "Includes a medical warning regarding photosensitivity.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.898+00", "seconds": 3.29, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/19", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-19", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.2, "w": 0.28, "x": 0.12, "y": 0.6 }, "kind": "callout", "text": "WARNING! The following contains bright, flashing lights and/or imagery that may cause discomfort and/or seizures for those with photosensitivity epilepsy. Viewer discretion is advised.", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4cc0cd12-4531-4437-84e8-1fa736af79ed", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.25, "x": 0.6, "y": 0.58 }, "kind": "image", "text": "CO2 inhalation mask", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Photo", "slug": "photo", "status": "active", "canonId": "019de52c-fd37-757f-b4a8-ca26d4888875", "version": 1, "description": null }, "framework": null }, "subkind": "photo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7d866874-ba04-4f44-aca4-609b75cfb624", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.04, "y": 0.21 }, "kind": "list", "text": "Epilepsy: Photosensitivity Study. The epilepsy photosensitivity model is a clinical translational model that provides proof-of-principle for antiepileptic activity in early clinical development. Testing new antiepileptic drugs in this clinical model can provide data that translates well into larger and other epilepsy populations", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ad09e55-54ca-4acb-990d-cfedba78bc46", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.45, "x": 0.51, "y": 0.21 }, "kind": "list", "text": "Acute Anxiety: Hypercapnia CO2 Inhalation Model. The CO2 inhalation challenge is a clinical translational model well-established in both healthy volunteers and in patients with panic disorder that provides proof-of-principle for anxiolytic activity in early clinical development. The model is sensitive to drugs used to treat anxiety disorders (including benzodiazepines & SSRIs) and emerging new treatments with novel mechanisms", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5913e470-a994-459d-94f5-01567edab55a", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "We plan to initiate two Phase 1b studies that we expect to translate well into later development programs", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.898+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "87b5bba1-5ba6-4a28-be12-17859e27cafa", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 20, "type": "setup", "title": "The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.", "function": "compare_peers", "rawType": "competitive_analysis", "block": null, "metadata": { "slideType": "competitive_analysis", "slideTypeCanon": { "name": "Competitive analysis", "slug": "competitive_analysis", "status": "active", "canonId": "019de52d-093e-776b-94c6-c1573f5f1a31", "version": 1, "description": null }, "function": "compare_peers", "functionCanon": { "name": "Compare peers", "slug": "compare_peers", "status": "active", "canonId": "019de52d-1453-72ba-a367-9ba3d34c1630", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 4, "textChars": 732, "nDataPoints": 20, "notes": "The slide uses a comparison table to frame BAER-101's selectivity profile as a competitive advantage.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.864+00", "seconds": 3.15, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/20", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-20", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.9, "x": 0.05, "y": 0.62 }, "kind": "list", "text": "BAER-101 is selective to the a2/3 receptor subunits and BAER-101 does not have high activity with the a5 subunit. Furthest along GABAa compound in clinical development is darigabat from Cerevel, which targets the a5 subunit in addition to the a2/3 receptor subunits.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "40039bd1-92dc-4063-a616-95aee77bb2bd", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.87, "x": 0.08, "y": 0.78 }, "kind": "list", "text": "Targeting the a5 receptor subunit is associated with tolerance development and this is potentially detrimental to developing a clinically effective drug for chronic use as resistance to the drug can occur over time. In addition, the a5 receptor subunit is also associated with sedation. BAER-101, unlike darigabat, is less likely to lead to treatment resistance and sedation.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "545f31a2-8f2b-40d8-be38-0b76aa15061e", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.9, "x": 0.05, "y": 0.21 }, "kind": "table", "text": "BAER-101 differentiation vs competitions", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d1a19fc8-3944-4232-a776-9ce62aae5d25", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.55, "x": 0.05, "y": 0.11 }, "kind": "title", "text": "BAER-101 is differentiated from others in the class", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72426462-0ef8-45f7-b0ab-1c93a4142cc8", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "2acfbd43-92c7-41fa-bce8-31e8e08a1a42", "evidence": "The slide uses a table to compare BAER-101 against competitors based on selectivity and clinical phase.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.864+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 20, "frameworkName": "comparison_frame" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 21, "type": "resolution", "title": "The slide uses a numbered process flow to outline corporate priorities.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 1, "textChars": 65, "nDataPoints": 0, "notes": "The slide uses a numbered process flow to outline corporate priorities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:07.743+00", "seconds": 2.023, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/21", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-21", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.4, "w": 0.8, "x": 0.1, "y": 0.3 }, "kind": "diagram", "text": "1. BAER-101, 2. IV Tramadol, 3. Acquire CNS / Rare Disease Assets", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:07.743+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e9b90d0-40ab-43e7-a4f3-ff568beadbeb", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "160e1178-f6de-41bb-9a63-152c764124c2", "evidence": "Three-step sequential roadmap", "framework": null, "confidence": 0.8, "extraction": { "at": "2026-05-02 12:27:07.743+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 21, "frameworkName": "process" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 22, "type": "setup", "title": "The slide uses a hub-and-spoke style diagram to illustrate the dual mechanism.", "function": "establish_context", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 5, "textChars": 562, "nDataPoints": 2, "notes": "The slide uses a hub-and-spoke style diagram to illustrate the dual mechanism.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.302+00", "seconds": 2.471, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/22", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-22", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.75 }, "kind": "callout", "text": "IV Tramadol has been safely used in Europe for 30 years – Approximately 370 million doses were administered in Europe from 2010 to 2019", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "629f475e-2aa4-4ac0-a290-e5f371b9709c", "parentComponentId": null }, { "bbox": { "h": 0.35, "w": 0.6, "x": 0.2, "y": 0.25 }, "kind": "diagram", "text": "Tramadol MOA: Opioid Efficacy with Less Abuse Potential", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Hub and spoke", "slug": "hub-spoke", "status": "active", "canonId": "019de52d-04db-73e6-81ca-a234f2f23fc1", "version": 1, "description": null }, "framework": null }, "subkind": "hub-spoke", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9bfee3b9-d761-4a95-b102-8694a1643707", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.5, "x": 0.25, "y": 0.65 }, "kind": "paragraph", "text": "Schedule IV versus Conventional Narcotics (Schedule II)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1e99d3d7-fecd-4ac0-8f3a-4475a02e2ed2", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.15, "y": 0.9 }, "kind": "source-note", "text": "Note: Schedule IV means a low potential for abuse and low risk of dependence. Schedule II drugs have a high potential for abuse, with use potentially leading to severe psychological or physical dependence. Source: https://www.dea.gov/druginfo/ds.shtml", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4311dbc2-96e4-4df0-a03c-bf02f0870f87", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.9, "x": 0.05, "y": 0.1 }, "kind": "title", "text": "Tramadol has a unique dual mechanism of action among IV analgesics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "92259090-8321-4c1e-98b7-3cb42425b53e", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "6539a2af-4d20-4d20-a5c9-315d52675615", "evidence": "Central circle with two side boxes connected by arrows", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.302+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 22, "frameworkName": "hub-spoke" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 23, "type": "resolution", "title": "The slide uses bar charts to demonstrate statistical significance (p < 0.001) of the drug over placebo in two different pain models.", "function": "analyze_data", "rawType": "key_takeaways", "block": null, "metadata": { "slideType": "key_takeaways", "slideTypeCanon": { "name": "Key takeaways", "slug": "key_takeaways", "status": "active", "canonId": "019de52d-06e7-7674-a891-9f7de3b11b6d", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 60, "componentCount": 6, "textChars": 350, "nDataPoints": 4, "notes": "The slide uses bar charts to demonstrate statistical significance (p < 0.001) of the drug over placebo in two different pain models.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.268+00", "seconds": 3.176, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/23", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-23", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.2 }, "kind": "callout", "text": "Both pain relief study models show benefit of Tramadol over placebo", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "202e0cb4-635f-4eed-ac71-114cde80fa29", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.92, "x": 0.04, "y": 0.83 }, "kind": "callout", "text": "IV Tramadol 50 mg achieved primary endpoint and all key secondary endpoints", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8ec0f873-529a-43e6-86be-2e3e6d699c46", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.04, "y": 0.3 }, "kind": "chart", "text": "Study AVE-901-102 (Bunionectomy) SPID24", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "eaaa3cb1-402b-4905-8f21-50a1ced22ef7", "parentComponentId": null }, { "bbox": { "h": 0.45, "w": 0.45, "x": 0.51, "y": 0.3 }, "kind": "chart", "text": "Study AVE-901-103 (Abdominoplasty) SPID24", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Grouped bar chart", "slug": "bar-grouped", "status": "active", "canonId": "019de52c-ff3b-751e-a8ff-f21ff11097b1", "version": 1, "description": null }, "framework": null }, "subkind": "bar-grouped", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f496012f-65ac-46f9-85db-520405046e34", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.35, "x": 0.55, "y": 0.79 }, "kind": "source-note", "text": "p-value is comparing IV tramadol to placebo.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8f695072-36a2-4648-a289-6c5394f17877", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.92, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "Safety and efficacy has been demonstrated in two Phase 3 trials in over 700 patients", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.268+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6884222c-afdd-4c7c-89b8-78054c286169", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 24, "type": "setup", "function": "summarize", "rawType": "timeline", "block": null, "metadata": { "slideType": "timeline", "slideTypeCanon": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-0851-75eb-b758-ea2965e7739a", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 72, "componentCount": 7, "textChars": 753, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:10.313+00", "seconds": 3.962, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/24", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-24", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.12, "w": 0.9, "x": 0.05, "y": 0.75 }, "kind": "callout", "text": "The Company intends to continue the dialogue with the FDA and submit a detailed protocol to gain alignment on a single safety study – the outcomes of this study could form the basis for resubmission of the NDA for IV tramadol", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8057b116-f7b4-4a79-9584-03e41fc578af", "parentComponentId": null }, { "bbox": { "h": 0.1, "w": 0.9, "x": 0.05, "y": 0.18 }, "kind": "diagram", "text": "2019, 2021, 2022", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "27d767ad-9e3c-4dbb-9a0d-ab389fe7cd73", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.15, "y": 0.92 }, "kind": "disclaimer", "text": "Additional details on the history of regulatory interactions, decisions, and meetings between Avenue and the FDA are available in our public filings with the Securities and Exchange Commission", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f769b8ae-6bd9-4ae7-88f1-21b13cd265ad", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.28, "x": 0.35, "y": 0.3 }, "kind": "list", "text": "February 2021: Resubmission. June 14, 2021: Second CRL regarding opioid stacking safety data.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1c26fa6e-6056-4b12-88bb-a7df7363d95d", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.3, "x": 0.65, "y": 0.3 }, "kind": "list", "text": "August 9, 2022: FDA meeting on study design for opioid stacking. FDA indicated proposed study design is reasonable.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4bb4cdcc-c75f-480a-83a6-7b7383673a76", "parentComponentId": null }, { "bbox": { "h": 0.2, "w": 0.28, "x": 0.05, "y": 0.3 }, "kind": "list", "text": "December 2019: NDA submission and October 2020 CRL.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Timeline item", "slug": "timeline-item", "status": "active", "canonId": "019de52c-fd0e-74ce-9443-440fbd8c23b4", "version": 1, "description": null }, "framework": null }, "subkind": "timeline-item", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d99cb269-0470-4b0c-90e1-9ec97358a4f4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.7, "x": 0.05, "y": 0.08 }, "kind": "title", "text": "Regulatory history and now a path forward for IV Tramadol NDA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "19eafd50-a3c2-4d26-9bcb-70fb470340c9", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "d529b528-b335-4eb5-ad25-224ed84c38ad", "evidence": "Chronological presentation of regulatory events", "framework": null, "confidence": 1, "extraction": { "at": "2026-05-02 12:27:10.313+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 24, "frameworkName": "timeline" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 25, "type": "resolution", "title": "The slide uses a numbered process flow to delineate strategic priorities.", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "sparse", "densityScore": 4, "componentCount": 1, "textChars": 60, "nDataPoints": 0, "notes": "The slide uses a numbered process flow to delineate strategic priorities.", "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:08.837+00", "seconds": 2.278, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/25", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-25", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.35, "w": 0.76, "x": 0.12, "y": 0.32 }, "kind": "diagram", "text": "1 BAER-101 2 IV Tramadol 3 Acquire CNS / Rare Disease Assets", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Process flow", "slug": "process", "status": "active", "canonId": "019de52d-039c-718f-ad3a-efe9c4b3c838", "version": 1, "description": null }, "framework": null }, "subkind": "process", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:08.837+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d2d877c-4b57-4085-88d7-72801cf72d1f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [ { "matchId": "2eec1bae-0a6e-4486-9195-f24f9535bf0a", "evidence": "Sequential numbered steps representing strategic focus areas.", "framework": null, "confidence": 0.9, "extraction": { "at": "2026-05-02 12:27:08.837+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 25, "frameworkName": "roadmap" } ], "arcBeats": [], "loops": [], "locked": true }, { "page": 26, "type": "setup", "title": "The slide uses a hexagonal layout to present selection criteria.", "function": "state_demand", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "state_demand", "functionCanon": { "name": "State demand", "slug": "state_demand", "status": "active", "canonId": "019de52d-180b-70a3-99c7-c832ea7db96b", "version": 1, "description": null }, "density": "balanced", "densityScore": 39, "componentCount": 5, "textChars": 222, "nDataPoints": 0, "notes": "The slide uses a hexagonal layout to present selection criteria.", "elementsJson": null, "confidence": 0.95, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.375+00", "seconds": 2.799, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/26", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-26", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.3, "w": 0.2, "x": 0.35, "y": 0.25 }, "kind": "diagram", "text": "Clinical Stage with Human Data", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.375+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "69d7becf-0368-4e3e-b23f-8f5d3df42938", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.05, "y": 0.25 }, "kind": "diagram", "text": "Imaging and Biomarker Driven Endpoints", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.375+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "cc81c010-95e4-4466-81d4-9321cb15f5f1", "parentComponentId": null }, { "bbox": { "h": 0.3, "w": 0.2, "x": 0.2, "y": 0.35 }, "kind": "diagram", "text": "Feasible Clinical Development Programs with Reasonable Costs", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": "other", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.375+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "de76c0e5-1915-485c-8a52-a924beb4bda5", "parentComponentId": null }, { "bbox": { "h": 1, "w": 0.35, "x": 0.65, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.375+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2ebe73b7-1121-4d1d-8583-e7a494b512e4", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.55, "x": 0.05, "y": 0.05 }, "kind": "title", "text": "We are searching the world for first rate CNS / rare disease assets with these characteristics", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.375+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e2dbd60-680b-4c22-920f-e385cdf3c970", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 27, "type": "setup", "function": "transition", "rawType": "section_divider", "block": null, "metadata": { "slideType": "section_divider", "slideTypeCanon": { "name": "Section divider", "slug": "section_divider", "status": "active", "canonId": "019de52d-066a-7402-9554-6ae504999041", "version": 1, "description": null }, "function": "transition", "functionCanon": { "name": "Transition", "slug": "transition", "status": "active", "canonId": "019de52d-1365-7149-92aa-66df859e75fd", "version": 1, "description": null }, "density": "sparse", "densityScore": 6, "componentCount": 2, "textChars": 47, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.616+00", "seconds": 2.566, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/27", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-27", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.055, "w": 0.138, "x": 0.036, "y": 0.925 }, "kind": "image", "text": "Avenue Therapeutics logo", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8d8699fb-c5cf-425f-ad49-e5520922007d", "parentComponentId": null }, { "bbox": { "h": 0.115, "w": 0.312, "x": 0.048, "y": 0.373 }, "kind": "title", "text": "Avenue Company Overview", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.616+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5c076dfa-4b18-4e12-96f7-f7e56ee97e4d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 28, "type": "setup", "function": "introduce_nominees", "rawType": "team_bio", "block": null, "metadata": { "slideType": "team_bio", "slideTypeCanon": { "name": "Team bio", "slug": "team_bio", "status": "active", "canonId": "019de52d-0a7d-7394-ae5b-037478e71f1e", "version": 1, "description": null }, "function": "introduce_nominees", "functionCanon": { "name": "Introduce nominees", "slug": "introduce_nominees", "status": "active", "canonId": "019de52d-1833-77fe-ac47-5f26d823a84a", "version": 1, "description": null }, "density": "dense", "densityScore": 59, "componentCount": 8, "textChars": 276, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:10.043+00", "seconds": 2.946, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/28", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-28", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.15, "w": 0.1, "x": 0.52, "y": 0.3 }, "kind": "image", "text": "Michael Ryan", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "17e22075-b7e2-4fa7-bd54-f3afef92ec0d", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.1, "x": 0.08, "y": 0.3 }, "kind": "image", "text": "Alexandra MacLean MD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "30e66c19-e8b7-46d0-842a-a1ccf5e62e33", "parentComponentId": null }, { "bbox": { "h": 0.15, "w": 0.1, "x": 0.3, "y": 0.3 }, "kind": "image", "text": "David Jin", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Headshot", "slug": "headshot", "status": "active", "canonId": "019de52c-fd5f-765c-9282-38b54f61bbbf", "version": 1, "description": null }, "framework": null }, "subkind": "headshot", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "36f18ca5-cc75-416c-b4ea-05c7091add79", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.6, "x": 0.04, "y": 0.6 }, "kind": "image", "text": "Company logos", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "47ac0aa2-6ed0-4785-8a42-7f36c3963735", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.25, "x": 0.7, "y": 0.28 }, "kind": "list", "text": "Lindsay Rosenwald MD, Jay Kranzler MD PhD, Neil Herskowitz, Curtis Oltmans, Faith Charles, E. Garrett Ingram, Jaideep Gogtay MD", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "01fad9f5-f10d-45eb-bd53-4889b5f6cbe9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.6, "x": 0.04, "y": 0.2 }, "kind": "title", "text": "Management", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "8b96e5b8-ee6b-459e-9fa0-e077e0d6af9f", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.7, "x": 0.04, "y": 0.06 }, "kind": "title", "text": "We are led by an experienced management team and board of directors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9013bc47-c256-490f-8990-6a86a7a079e0", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.7, "y": 0.2 }, "kind": "title", "text": "Board of Directors", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:10.043+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ee366ec4-21cc-44a7-bec9-20cb0a2eb916", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 29, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 28, "name": "Team", "beatId": "082cf897-b0c1-43e2-90f2-e35450751b09", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 28 and 29 present the management team and board of directors.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 29, "type": "setup", "function": "establish_context", "rawType": "appendix_disclosure", "block": null, "metadata": { "slideType": "appendix_disclosure", "slideTypeCanon": { "name": "Appendix disclosure", "slug": "appendix_disclosure", "status": "active", "canonId": "019de52d-07b2-7549-8e8b-932a19f6e616", "version": 1, "description": null }, "function": "establish_context", "functionCanon": { "name": "Establish context", "slug": "establish_context", "status": "active", "canonId": "019de52d-1314-74e6-9074-d213dc0bdcdf", "version": 1, "description": null }, "density": "dense", "densityScore": 64, "componentCount": 5, "textChars": 691, "nDataPoints": 4, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:09.634+00", "seconds": 2.444, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/29", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-29", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 0.1, "w": 0.85, "x": 0.04, "y": 0.63 }, "kind": "list", "text": "Proprietary dosing regimen is patent-protected in the US until 2036, excluding patent term extension\nPortfolio also includes drug patents covering combinations", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.634+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "dff5317d-fabe-4039-857f-e705bda81f07", "parentComponentId": null }, { "bbox": { "h": 0.25, "w": 0.92, "x": 0.04, "y": 0.23 }, "kind": "list", "text": "Two issued US patents and related foreign patents in European States (CH, DE, ES, FR, GB, IT and SE), China, Canada and Japan for composition of matter with expiry date of December 2026\nEligible for patent term extension (expected 5 years)\nPotential for Orphan Drug Designation for rare epilepsies (7 years market exclusivity)\nTwo issued US patents for method of use in a childhood development disorder with expiry date of January 2036\nAdditional IP under development for specific indication needs", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.634+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f1c6aaea-0922-449f-839c-58893f35bf92", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.11, "x": 0.04, "y": 0.58 }, "kind": "paragraph", "text": "IV Tramadol", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.634+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "72d9e649-f30c-4013-94b7-eb4f98ee9911", "parentComponentId": null }, { "bbox": { "h": 0.03, "w": 0.08, "x": 0.04, "y": 0.18 }, "kind": "paragraph", "text": "BAER-101", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.634+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "974f2e25-828d-4a17-904c-22b670b0e8ca", "parentComponentId": null }, { "bbox": { "h": 0.04, "w": 0.23, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "IP / Exclusivity", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:09.634+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "1d0ea79f-fbca-477d-8096-b4efc19c8c7f", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 29, "arc": { "name": "The Sequoia Pitch", "slug": "sequoia-pitch", "status": "active", "bestFor": "Investor pitches, Series A/B, board presentations", "canonId": "019dd956-5e69-75a7-a0a4-895ac1bc0444", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Problem -> Solution -> Why Now -> Market Size -> Competition -> Product -> Business Model -> Team -> Financials -> The Ask", "description": null, "familyLabel": null }, "from": 28, "name": "Team", "beatId": "082cf897-b0c1-43e2-90f2-e35450751b09", "matchId": "1d1c746f-e12a-4c9b-ad85-ad559b9acc78", "beatType": { "name": "Team", "slug": "sequoia-pitch-team", "status": "active", "canonId": "019dd9b8-23c9-746f-aaf9-2f5d83892cf3", "version": 1, "description": null }, "evidence": "Slides 28 and 29 present the management team and board of directors.", "position": 4, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 30, "type": "setup", "function": "summarize", "rawType": "executive_summary", "block": null, "metadata": { "slideType": "executive_summary", "slideTypeCanon": { "name": "Executive summary", "slug": "executive_summary", "status": "active", "canonId": "019de52d-06be-73ff-81b3-f99fe7f0025e", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 50, "componentCount": 4, "textChars": 722, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "at": "2026-05-02 12:27:14.193+00", "seconds": 6.908, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de073-a59c-77cf-8e75-229e6c5c9530/30", "deck": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530", "deckAnchor": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530#slide-30", "deckJson": "/decks/019de073-a59c-77cf-8e75-229e6c5c9530.json" }, "components": [ { "bbox": { "h": 1, "w": 0.38, "x": 0.62, "y": 0 }, "kind": "image", "text": null, "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Illustration", "slug": "illustration", "status": "active", "canonId": "019de52c-fe76-7772-a5ac-c0b7294d7615", "version": 1, "description": null }, "framework": null }, "subkind": "illustration", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:14.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2b88932d-af30-4fb8-89fa-4ad0df884dd5", "parentComponentId": null }, { "bbox": { "h": 0.6, "w": 0.55, "x": 0.04, "y": 0.2 }, "kind": "list", "text": "Avenue Therapeutics is a specialty pharmaceutical company that seeks to develop and commercialize therapies to treat central nervous system (CNS) conditions. Our portfolio will soon include two clinical stage programs that we believe each have a significant market potential: IV Tramadol (Phase 3) for acute postoperative surgical pain and BAER-101* (Phase 1b) for epilepsy and acute anxiety. Our clinical development programs are designed to meet near-term milestones that could build near-term value. Potential to continue to expand pipeline through additional acquisitions in the rare / CNS disease space.", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:14.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "086f14ef-ca98-486e-bba9-71e4c46401ba", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.35, "x": 0.18, "y": 0.93 }, "kind": "source-note", "text": "* Pending close of Share Contribution Agreement with Fortress Biotech, Inc. for Baergic Bio, Inc.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:14.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4625812e-1dc5-4e2a-8166-2c86cfcae3f4", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.25, "x": 0.04, "y": 0.11 }, "kind": "title", "text": "Executive Summary", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 12:27:14.193+00", "model": "google/gemini-3.1-flash-lite-preview-20260303", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5808029f-e5db-4147-a146-5985904c5c12", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 11, "to": 12, "label": "Problem", "description": "Slides 11 and 12 present the problem statement, highlighting the unmet needs in epilepsy and acute anxiety treatment." }, { "from": 8, "to": 10, "label": "Solution", "description": "Slides 8-10 present BAER-101 as a solution, describing its mechanism of action and therapeutic potential." }, { "from": 13, "to": 14, "label": "Market Size", "description": "Slides 13 and 14 present the market opportunity for BAER-101." }, { "from": 15, "to": 16, "label": "Product", "description": "Slides 15 and 16 present preclinical data supporting the efficacy of BAER-101." }, { "from": 28, "to": 29, "label": "Team", "description": "Slides 28 and 29 present the management team and board of directors." } ], "loops": [ { "from": 11, "to": 14, "label": "Cost Of Inaction", "description": "What are the consequences of not addressing the unmet needs in epilepsy and acute anxiety treatment?" } ] }